Trial Profile
Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Infliximab (Primary) ; Prednisolone (Primary) ; Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms RIMINI
- 08 Jun 2022 Primary endpoint has been met. (1) Composite endpoint of efficacy failure of the induction regimen defined as occurrence of any of the following individual outcomes up to 12 months post transplantation (start of follow up at transplantation): acute rejection, graft loss or poor graft function defined as eGFR40 ml/min.)
- 08 Jun 2022 Results presented at the 2022 American Transplant Congress
- 19 Mar 2022 This trial has been completed in Spain (Global End Date: 31 Dec 2020), according to European Clinical Trials Database record.